Piramal plans UK investments, renews contract with Pfizer

14 October 2009 15:15  [Source: ICIS news]

MADRID (ICIS news)--Piramal Healthcare Pharma Solutions plans a £1m ($1.6m, €1.1m) upgrade to its high-potency substances (HPS) production facility in Grangemouth, UK, the India-based producer of active pharmaceutical ingredients said on Wednesday.

The investment, announced at the CPhI Worldwide pharmaceutical ingredients exhibition, will prepare and validate one of six production suites for the commercial-scale production of antibody-drug conjugates (ADCs), according to a company official.

The production suite will be used to manufacture an ADC now in “pivotal” clinical trials for “a leading US biotech company,” the official said.

Piramal simultaneously made announcements concerning its UK biocatalysis division and its Morpeth production facility.

Supply contracts with Pfizer that were originally negotiated as part of the sale of the Morpeth site to Piramal have been renewed and expanded in the form of a long-term partnership, the company said. Piramal will continue to produce active pharmaceutical ingredients (APIs), bulk formulated products and finished dosage forms for Pfizer.

Piramal also announced the relocation of its UK biocatalysis division to custom laboratory facilities in Wilton, Teesside, UK.

Bob Holt, technical director of the biocatalysis division, said the move will help to target customer opportunities in both developmental compounds and launched products.

($1 = £0.62/€0.67)

To discuss issues facing the chemical industry go to ICIS connect

By: Clay Boswell
+1 713 525 2653

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly